Drug Profile

PF 6412562

Alternative Names: PF-06412562; PF-6412562

Latest Information Update: 05 Aug 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Pfizer
Developer Cerevel Therapeutics; Pfizer; Yale University
Class Antiparkinsonians; Nootropics; Small molecules
Mechanism of Action Dopamine receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I/II Schizophrenia
Discontinued Cognition disorders; Parkinson's disease

Most Recent Events

01 Aug 2024 Cerevel Therapeutics has been acquired by AbbVie
15 Feb 2021 Phase I/II clinical trials in Schizophrenia in USA (PO)(NCT04457310)
07 Jul 2020 Yale University in collaboration with Cerevel Therapeutics plans a phase I/II trial for Schizophrenia (PO) in August 2020 (NCT04457310)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com